Related Experiment Video
Updated: Mar 15, 2026
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting
Giannis Mountzios1, Helena Linardou2, Paris Kosmidis3
1Department of Medical Oncology, University of Athens School of Medicine, Athens, Greece ;
Abstract:
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide. In recent years, through a better understanding of the interactions between the immune system and tumor cells (TC), immunotherapy has emerged as a promising therapeutic strategy. Chemotherapy has long been reported to interfere with the immune response to the tumor and conversely, anti-tumor immunity may add to those effects. Anti-tumor vaccines, such as MAGE-A3, Tecetomide, TG4010, CIMAvax, tumor cell vaccines and dendritic cell (DC) vaccines emerged as potent inducers of the immune response against the tumor. More recently the approval of the anti-programmed cell death 1 (anti-PD-1) monoclonal antibodies nivolumab and pembrolizumab for previously treated advanced squamous and non-squamous NSCLC, as well as other immune checkpoint inhibitors delivering promising results, has radically transformed the therapeutic landscape of NSCLC. Combination strategies now appear as the next step. Notwithstanding these successes, immunotherapy still holds significant drawbacks and currently several improvements are needed before routine use in clinical practice, including identification of robust biomarkers for optimal patient selection, as well as defining the best way to evaluate response.
Insights
Immunotherapy, including vaccines and immune checkpoint inhibitors like anti-PD-1, shows promise for non-small cell lung cancer (NSCLC). Further research is needed to optimize patient selection and response evaluation for broader clinical use.
Area of Science:
- Oncology
- Immunology
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Understanding tumor-immune cell interactions has led to immunotherapy as a key strategy.
- Chemotherapy can influence anti-tumor immunity, and vice versa.
Purpose of the Study:
- To review the advancements in immunotherapy for NSCLC.
- To highlight the emergence of vaccines and immune checkpoint inhibitors.
- To discuss the future directions and challenges in NSCLC immunotherapy.
Main Methods:
- Review of current immunotherapy approaches for NSCLC.
- Analysis of vaccine-based and immune checkpoint inhibitor therapies.
- Discussion of combination strategies and future research needs.
Main Results:
- Immunotherapy, including vaccines (MAGE-A3, Tecetomide, TG4010, CIMAvax, tumor cell, and dendritic cell vaccines), has emerged as a potent strategy.
- Immune checkpoint inhibitors, specifically anti-programmed cell death 1 (anti-PD-1) antibodies (nivolumab, pembrolizumab), have transformed NSCLC treatment.
- Combination strategies are the next frontier in NSCLC immunotherapy.
Conclusions:
- Immunotherapy has revolutionized NSCLC treatment, offering new hope.
- Significant challenges remain, including biomarker identification for patient selection and response assessment.
- Further improvements are necessary for the routine clinical application of NSCLC immunotherapies.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...